Lipocine to Present at Biotech Showcase 2024
Company Management Will Also Host Meetings at LifeSci Partners Corporate Access Event
SALT LAKE CITY, Dec. 19, 2023 /PRNewswire/ — Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that it will present at the Biotech Showcase and host institutional investor and partnering meetings at this event and at a Corporate Access Event organized by LifeSci Partners. Both in-person events will take place January 8 – 10, 2024, in San Francisco, California.
Related news for (LPCN)
- Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD)
- Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2025
- Lipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum Depression
- Lipocine to Host Virtual R&D Investor Event to Discuss LPCN 1154 (BRLIZIO™) as a Treatment for Postpartum Depression on July 9, 2025
- 24/7 Market News Snapshot 09 June, 2025 – Lipocine Inc. (NASDAQ:LPCN)